This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Borchardt, P. E. Articles by Scheinberg, D. A. Search for Related Content PubMed PubMed Citation Articles by Borchardt, P. E. Articles by Scheinberg, D. A.

Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer¹

Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Advanced ovarian cancer is largely incurable, but initially it is frequently confined to the i.p. space. We explored i.p. radioimmunotherapy in a mouse model of human ovarian cancer. Use of a targeted actinium-225 (²²⁵Ac) in vivo generator of particles exploits the extreme, selective cytotoxicity of particles, while providing a feasible half-life to enable delivery to tumor. ²²⁵Ac chelated with 2-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraacetic acid was conjugated to trastuzumab, an anti-HER-2/neu antibody. The radioimmunoconjugate was tested for immunoreactivity, internalization, and cytotoxicity using a human ovarian carcinoma cell line, SKOV3. ²²⁵Ac-labeled trastuzumab retained immunoreactivity (50–90%), rapidly internalized into cells (50% at 2 h), and had an ED₅₀ of 1.3 nCi/ml after 4 days of incubation in vitro. i.p. administered ²²⁵Ac- or ¹¹¹In-labeled trastuzumab behaved similarly with high tumor uptake [56–60% injected dose per gram (% ID/g) at 4 h, which increased to 65–70% ID/g at 24 h]. Tumor uptake was 3–5-fold higher than liver and spleen, the normal organs with the highest uptake. i.v. administration of ¹¹¹In-labeled trastuzumab produced slightly higher normal organ uptake compared with i.p.-administered ¹¹¹In-labeled trastuzumab. However, tumor uptake was low, 5%–26% ID/g. Therapy was examined with native trastuzumab and 220, 330, and 450 nCi of ²²⁵Ac-labeled trastuzumab or ²²⁵Ac-labeled control antibody at different dosing schedules. Therapy was initiated 9 days after tumor seeding. Groups of control mice and those administered native trastuzumab had median survivals of 33 and 37 or 44 days, respectively. Median survival was 52–126 days with ²²⁵Ac-labeled trastuzumab at various doses and schedules, and 48–64 days for ²²⁵Ac-labeled control the same schedules. Deaths from toxicity occurred with the highest activity levels. In conclusion, i.p. administration with a ²²⁵Ac-labeled internalizing anti-HER-2/neu antibody can extend survival significantly in a nude mouse model of human ovarian cancer at levels that produce no apparent gross toxicity.

This article has been cited by other articles:

				H. Song, K. Shahverdi, D. L. Huso, C. Esaias, J. Fox, A. Liedy, Z. Zhang, R. T. Reilly, C. Apostolidis, A. Morgenstern, et al. 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model Cancer Res., May 15, 2008; 68(10): 3873 - 3880. [Abstract] [Full Text] [PDF]

				M. K. Robinson, C. Shaller, K. Garmestani, P. S. Plascjak, K. M. Hodge, Q.-A. Yuan, J. D. Marks, T. A. Waldmann, M. W. Brechbiel, and G. P. Adams Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the {alpha}-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies Clin. Cancer Res., February 1, 2008; 14(3): 875 - 882. [Abstract] [Full Text] [PDF]

				M. P. Kelly, F. T. Lee, K. Tahtis, F. E. Smyth, M. W. Brechbiel, and A. M. Scott Radioimmunotherapy with {alpha}-Particle Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5604s - 5612s. [Abstract] [Full Text] [PDF]

				D. J. Nolan, A. Ciarrocchi, A. S. Mellick, J. S. Jaggi, K. Bambino, S. Gupta, E. Heikamp, M. R. McDevitt, D. A. Scheinberg, R. Benezra, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes & Dev., June 15, 2007; 21(12): 1546 - 1558. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Adjuvant and Combined Radioimmunotherapy: Problems and Prospects on the Road to Minerva J. Nucl. Med., November 1, 2006; 47(11): 1746 - 1748. [Full Text] [PDF]

				S. Bloechl, R. Beck, C. Seidl, A. Morgenstern, M. Schwaiger, and R. Senekowitsch-Schmidtke Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal Antibody Clin. Cancer Res., October 1, 2005; 11(19): 7070s - 7074s. [Abstract] [Full Text] [PDF]

				J. S. Jaggi, S. V. Seshan, M. R. McDevitt, K. LaPerle, G. Sgouros, and D. A. Scheinberg Renal Tubulointerstitial Changes after Internal Irradiation with {alpha}-Particle-Emitting Actinium Daughters J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2677 - 2689. [Abstract] [Full Text] [PDF]

				J. Singh Jaggi, B. J. Kappel, M. R. McDevitt, G. Sgouros, C. D. Flombaum, C. Cabassa, and D. A. Scheinberg Efforts to Control the Errant Products of a Targeted In vivo Generator Cancer Res., June 1, 2005; 65(11): 4888 - 4895. [Abstract] [Full Text] [PDF]

				R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and C. Divgi Current Status of Therapy of Solid Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S. [Abstract] [Full Text] [PDF]

				D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, D. Ma, A. Abdulla, and M. W. Brechbiel Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease Clin. Cancer Res., December 1, 2004; 10(23): 7834 - 7841. [Abstract] [Full Text] [PDF]

				R. R. Yuan, P. Wong, M. R. McDevitt, E. Doubrovina, I. Leiner, W. Bornmann, R. O'Reilly, E. G. Pamer, and D. A. Scheinberg Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers Blood, October 15, 2004; 104(8): 2397 - 2402. [Abstract] [Full Text] [PDF]

				A. M. Ballangrud, W.-H. Yang, S. Palm, R. Enmon, P. E. Borchardt, V. A. Pellegrini, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression Clin. Cancer Res., July 1, 2004; 10(13): 4489 - 4497. [Abstract] [Full Text] [PDF]